Format

Send to

Choose Destination
See comment in PubMed Commons below
QJM. 2012 Feb;105(2):189-93. doi: 10.1093/qjmed/hcq248. Epub 2011 Jan 21.

Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy.

Author information

1
Department of Paediatrics, Royal Devon & Exeter Hospital, Exeter, UK. pamelabowman@nhs.net

Abstract

Maternal thyrotoxicosis, predominantly secondary to Graves' disease, affects 0.2% of all pregnancies. The Endocrine Society guidelines recommend the use of propylthiouracil as a first-line drug for thyrotoxicosis in pregnancy because of associations between carbimazole or methimazole and congenital anomalies. However, recent studies have highlighted the risk of severe liver injury with propylthiouracil. Here, we report another case with multiple congenital anomalies following in utero exposure to carbimazole and review the literature to consider the risks and benefits of available pharmacological treatments for thyrotoxicosis in pregnancy.

PMID:
21258054
DOI:
10.1093/qjmed/hcq248
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center